Prostate Cancer

The eruption was refractory to treatment, despite the patient withholding lorigerlimab, leading to complete discontinuation of lorigerlimab. This report highlights the importance of histopathologic evaluation in guiding treatment decisions for lorigerlimab-associated irAEs and underscores the need for further research into its dermatologic irAEs.

It also reduced SLC7A11 expression, suggesting a disruption of redox homeostasis in cancer cells. Taken together, this integrated strategy combining molecular targeting, real-time imaging, and localized mPTT, with optional gene regulation, offers a promising theranostic approach for precision management of PCa.

Targeting glycolysis presents novel opportunities to address existing limitations in PCa management. This review discusses the advances, challenges, and future research directions in glycolysis-focused PCa studies, providing a theoretical foundation for the development of precise metabolic interventions.

In contrast, it spared non-tumorigenic prostate epithelial cells (PCS-440-010), unlike Docetaxel...Western blot analysis revealed no change in the caspase-8 expression, but a marked upregulation of Beclin-1, probably related to autophagy cell death pathways. These findings highlight the selective cytotoxicity and anti-metastatic potential of Pllans-II, positioning it as a promising prototype for the development of novel therapeutic strategies against prostate cancer.

In this RP cohort, GPS modestly improved prediction of adverse pathology beyond PSA density and MRI, with clinical utility primarily in favorable intermediate-risk patients, where treatment decisions between active surveillance and definitive therapy are uncertain. These findings suggest selective, risk-adapted application of GPS to guide treatment decision-making. Validation in prospective, diverse cohorts is warranted.

In treatment-naïve PaNED, higher SIS was correlated with lower PD-L1 CPS values, and strong synaptophysin expression was associated with poorer survival. Assessment of SIS in morphologically suspected neuroendocrine areas may provide additional prognostic information and help predict the PD-L1 response. Larger studies are required to validate these findings.

This study provides real-world evidence of the epidemiology and therapeutic patterns of PC, thereby enhancing the understanding of the current clinical landscape in Korea.

We observed no changes in markers of insulinemia, inflammation, or PSA from a 16-week at-home walking intervention vs. control in individuals with low-risk PCa.

P=N/A, N=208, Recruiting, University of Pittsburgh | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026

P1/2, N=35, Completed, Advanced Accelerator Applications | N=71 --> 35

P1, N=56, Recruiting, Alessa Therapeutics Inc. | N=20 --> 56 | Trial completion date: Aug 2025 --> Aug 2028 | Trial primary completion date: Jun 2025 --> Jun 2028

P=N/A, N=160, Recruiting, Henry Ford Health System